NewsPress Release Cortexyme Provides Business Update and Reports First Quarter 2021 Results By admin | News, Press Release
NewsPress Release Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease By admin | News, Press Release
NewsPress Release Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion By admin | News, Press Release
NewsPress Release Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones By admin | News, Press Release
EventsPress Release Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis By admin | Events, Press Release
EventsPress Release Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences By admin | Events, Press Release
Press Release Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients By admin | Press Release
NewsPress Release Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office By admin | News, Press Release
NewsPress Release Cortexyme Presents Data Linking P. gingivalis to Cardiovascular Disease Severity and AD, Along With Evidence That Atuzaginstat Improves Biomarkers For Both By admin | News, Press Release
Press Release Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update By admin | Press Release
